A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis

Summary

The purpose of this study is to evaluate safety and tolerability of JNJ 66525433 compared with placebo after administration of: 1) single ascending oral doses of JNJ 66525433 administered to healthy participants (Part 1), 2) multiple, ascending oral doses of JNJ 66525433, administered to healthy participants once daily over 14 consecutive days (Part 2), and 3) multiple oral doses of JNJ 66525433, administered once daily over 14 consecutive and once daily over 42 consecutive days in participants with ulcerative colitis (UC) (Part 3).

Timeline

Start

2020-07-01

Primary completion

2021-10-13

Completion

2021-10-13

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision.”

Drugs

Indications